argenex (NASDAQ:ARGX) Price Target Raised to $940.00

argenex (NASDAQ:ARGX) had its target price boosted by HC Wainwright from $915.00 to $940.00 in a report published on Friday,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms also recently commented on ARGX. TD Cowen boosted their price target on shares of argenex from $800.00 to $1,146.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Morgan Stanley upped their price target on argenex from $1,070.00 to $1,110.00 and gave the stock an “overweight” rating in a report on Thursday, December 4th. Wolfe Research reaffirmed a “peer perform” rating on shares of argenex in a research report on Monday, November 24th. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research report on Wednesday, January 21st. Finally, Citigroup reduced their target price on shares of argenex from $1,124.00 to $1,091.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, argenex has an average rating of “Moderate Buy” and a consensus target price of $999.22.

argenex Stock Performance

Shares of argenex stock opened at $766.92 on Friday. The business’s 50 day moving average price is $826.36 and its 200 day moving average price is $813.13. The company has a market cap of $47.46 billion, a price-to-earnings ratio of 39.29, a PEG ratio of 1.16 and a beta of 0.38. argenex has a one year low of $510.05 and a one year high of $934.62.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, February 26th. The company reported $8.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.05 by $1.97. argenex had a net margin of 30.42% and a return on equity of 38.51%. The business had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.30 billion. On average, analysts predict that argenex will post 3.13 EPS for the current fiscal year.

Institutional Trading of argenex

A number of institutional investors have recently added to or reduced their stakes in the stock. Abound Wealth Management boosted its position in argenex by 3,200.0% during the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after purchasing an additional 32 shares in the last quarter. Sound Income Strategies LLC acquired a new position in shares of argenex during the 4th quarter worth $28,000. Ameriflex Group Inc. purchased a new stake in shares of argenex in the 3rd quarter worth about $32,000. Sunbelt Securities Inc. purchased a new stake in shares of argenex in the 3rd quarter worth about $36,000. Finally, Aventura Private Wealth LLC acquired a new stake in argenex in the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Key Stories Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase‑3 topline results for VYVGART in ocular myasthenia gravis (ADAPT OCULUS); study met its primary endpoint and argenx plans a supplemental BLA submission to expand the label into oMG, which materially expands commercial opportunity. argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial
• Positive Sentiment: Strong quarterly and full‑year commercial performance: $1.3B in Q4 product net sales and $4.2B for FY2025 (≈90% YoY growth), reinforcing revenue momentum and the company’s commercialization traction. argenx Reports Full Year 2025 Financial Results
• Positive Sentiment: Q4 beat on the numbers: $8.02 EPS vs. $6.05 consensus and $1.32B revenue vs. $1.30B consensus, with healthy margins and ROE — data that supports higher earnings expectations. MarketBeat Q4 Earnings Summary
• Positive Sentiment: Certain sell‑side firms raised targets after the results (Citizens JMP and HC Wainwright among them), signaling continued analyst conviction in upside from commercialization and label expansion. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Other major firms trimmed price targets (Wells Fargo, Guggenheim, RBC) but generally maintained positive ratings (overweight/outperform/buy). These adjustments temper upside expectations but keep buy convictions intact. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Reports flag a “large increase” in short interest for February, but the published short‑interest numbers appear inconsistent/erroneous (zeros/NaN). As reported data is unreliable, the market impact is unclear.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.